20/20 HealthCare Partners
  • Home
  • What Differentiates 20/20 HCP
  • Team
  • Companies
    • Companies
    • Exits
  • News
  • Contact

20/20 HealthCare Partners

19 Nov2021

XRHealth On-demand virtual care reinvented: Revolutionizing Telehealth with VR/AR

Written by 2020HCP.com. Posted in News

Reasons to Invest

  • XRHealth has generated over $1 million in revenue YTD and treated over 2,000 patients. QoQ growth has been 40+% in 2021. With $20M raised to-date from crowdfunding, angel investors, AARP, VCs, and grant-making institutions, we have demonstrated success in fundraising. With this new funding round, we believe we will be able to maintain this robust growth trajectory.
  • Unique Technology in a Large Market: The fast-growth Telehealth Market is predicted to reach a value of $70.19 billion by 2026. XRHealth VR/AR Medical technology generates valuable objective data points and allows telehealth clinicians to tailor individualized treatment plans for each patient. We are protecting our VR/AR telehealth intellectual property through the pursuit of 21 patents (3 approved). 
  • Patient Satisfaction and Clinical Outcomes: We have strong patient satisfaction, evidenced by XRHealth NPS (Net Promoter Score) of 74 (vs healthcare market average of 38) with 72% of patients agreeing we made a positive difference in their symptoms in under two weeks.

READ MORE

Latest News

  • Variantyx Secures $20M Debt Financing to Support Precision Medicine in North America, Europe October 18, 2022
  • SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting June 21, 2022
  • SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors April 28, 2022
  • SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo April 11, 2022
  • SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes April 5, 2022

20/20 HealthCare Partners | 2000 Commonwealth Ave, Suite 200, Auburndale, MA 02466 | Contact Us

Copyright © 2019
  • Home
  • What Differentiates 20/20 HCP
  • Team
  • Companies
    • Companies
    • Exits
  • News
  • Contact